ANTIBODY-MEDIATED REJECTION
Clinical trials for ANTIBODY-MEDIATED REJECTION explained in plain language.
Never miss a new study
Get alerted when new ANTIBODY-MEDIATED REJECTION trials appear
Sign up with your email to follow new studies for ANTIBODY-MEDIATED REJECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could save transplanted kidneys from immune attack
Disease control Recruiting nowThis study tests a drug called felzartamab in 120 kidney transplant patients whose bodies are attacking their new kidney (antibody-mediated rejection). The drug targets immune cells that make harmful antibodies, aiming to stop damage and keep the kidney working. Participants will…
Matched conditions: ANTIBODY-MEDIATED REJECTION
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 17, 2026 08:51 UTC
-
New shot may help stop kidney rejection
Disease control Recruiting nowThis study tests a new drug called efgartigimod for people who have kidney transplant rejection caused by antibodies. About 30 adults who had a kidney transplant at least 6 months ago and have active rejection will receive the drug or a placebo as a shot under the skin. They will…
Matched conditions: ANTIBODY-MEDIATED REJECTION
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated May 17, 2026 08:46 UTC
-
New hope for kidney transplant patients: drug trial targets rejection
Disease control Recruiting nowThis study tests a new drug called ALXN2030 in 45 adults who have had a kidney transplant and are experiencing antibody-mediated rejection (AMR), where the body attacks the new kidney. The goal is to see if the drug can help resolve the rejection better than a placebo over 52 wee…
Matched conditions: ANTIBODY-MEDIATED REJECTION
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC